Who are Lipanor's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lipavil, duvie, Lipaglyn, Lopid, fenofibrate/omega, ANTARA® (fenofibrate).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ciprofibrate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Lipanor — Competitive Intelligence Brief

Lipanor (CIPROFIBRATE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ciprofibrate. Area: Metabolic.

marketed ciprofibrate Peroxisome proliferator-activated receptor alpha Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Lipanor (CIPROFIBRATE) — Winthrop Pharmaceuticals UK Limited.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lipanor TARGET	CIPROFIBRATE	Winthrop Pharmaceuticals UK Limited	marketed	ciprofibrate	Peroxisome proliferator-activated receptor alpha	1985-01-01
Lipavil	CLOFIBRATE		marketed	clofibrate	Peroxisome proliferator-activated receptor alpha	1967-01-01
duvie	duvie	Pusan National University Hospital	marketed		Peroxisome proliferator-activated receptor alpha, Peroxisome proliferator-activated receptor gamma
Lipaglyn	SAROGLITAZAR	Cadila Healthcare	marketed		Peroxisome proliferator-activated receptor alpha
Lopid	Gemfibrozil	Pfizer Inc.	marketed	Peroxisome Proliferator Receptor alpha Agonist [EPC]	PPAR-alpha (Peroxisome Proliferator-Activated Receptor Alpha)
fenofibrate/omega	fenofibrate/omega	Gachon University Gil Medical Center	marketed	Fibrate + omega-3 fatty acid combination	PPARα (peroxisome proliferator-activated receptor alpha)
ANTARA® (fenofibrate)	ANTARA® (fenofibrate)	Ranbaxy Laboratories Limited	marketed	Fibrate (PPARα agonist)	PPARα (Peroxisome proliferator-activated receptor alpha)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ciprofibrate class)

Winthrop Pharmaceuticals UK Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lipanor — Competitive Intelligence Brief. https://druglandscape.com/ci/ciprofibrate. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab